- Home
- PMO vs VNDA Comparison
PMO vs VNDA Comparison
Compare PMO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMO | VNDA |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.4M | 301.1M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PMO | VNDA |
|---|---|---|
| Price | $9.05 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 92.1K | ★ 639.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $25.02 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.02 | $4.27 |
| 52 Week High | $10.87 | $9.91 |
Technical Indicators
Market Signals| Indicator | PMO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 18.93 | 43.70 |
| Support Level | N/A | $4.94 |
| Resistance Level | $10.80 | $5.62 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 2.00 | 25.22 |
Price Performance
Historical ComparisonAbout PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, leases, local, Housing, education, and Others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.